LUMIRADX UK LTD

• ◆

  1 PSC ceased in last 24 months

  Significant control changed hands — see the Ownership section.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  -49.5%

  £24,188,703 → £12,210,431

• Cash

  +188.1%

  £2,048,282 → £5,900,174

• Net assets

  -144.3%

  £67,872,137 → -£30,074,588

• Employees

  -31%

  538 → 371

• Operating profit

  -11.5%

  -£119,987,397 → -£133,842,843

• Profit before tax

  +14.9%

  -£158,695,798 → -£135,091,041

• Wages

  -17.4%

  £28,451,783 → £23,502,379

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.

1. LUMIRADX UK LTD 2016-05-25 → present
2. LUMIRA LTD 2015-04-08 → 2016-05-25
3. AEGLE CARE LTD 2014-09-17 → 2015-04-08
4. AEGLE TECHNOLOGY LTD 2014-09-05 → 2014-09-17

Accounting basis

UK-adopted IFRS

Reporting scope

Standalone (parent only)

Auditor

KPMG LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The financial statements are prepared on a going concern basis as the directors have assessed the ability of the company to continue trading for a minimum period of 12 months from the date of authorising these financial statements. The directors have obtained a letter of financial support from the Company's parent entity, Roche Diagnostics Limited, and assessed the ability of the parent to provide the levels of financial assistance required to enable the company to meet its financial obligations as they fall due. Based on the above, the directors believe it is appropriate to prepare the financial statements on a going concern basis.”

Group structure

1. LUMIRADX UK LTD · parent
   1. SureSensors Limited 100% · England · Manufacturer of medical diagnostics

Significant events

• “On 22 January 2025 the company announced the start of employee consultations, with the new organisation being announced on 31 March 2025. It was also announced that activities would commence to close the sites in Thurleigh, Scion House (2025), Manor Loan and Dumyat (2026), transferring activities and staff to create centres of excellence for manufacturing and research and development in Motherwell.”
• “On 1 April 2025 the commercialisation activities to market, distribute and service the LumiraDx point of care diagnostics equipment to the UK and Irish healthcare markets was transferred to Roche Diagnostics Limited. Also, at this date LumiraDx UK limited ceased being the central entrepreneur for the LumiraDx legal entities with future focus on manufacturing and contract research and development of LumiraDx's transformative Point of Care solution for the Roche Group.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

4

last 12 months

Capital events

0

last 24 months

Officers appointed

2

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.